drugset / Trial / NCT01799538

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

NCT01799538

Phase 1/2 Recruiting 100 enrolled National Heart, Lung, and Blood Institute (NHLBI)
RandomizedParallel-groupOpen-labelTreatment

Summary

Background: \- Lymphangioleiomyomatosis (LAM) is a rare type of lung disease that occurs almost exclusively in women. In LAM, muscle tissue grows in the lungs and starts to block the flow of air. It is a progressive disease, and in severe cases may require a lung transplant. One possible treatment to improve breathing in people with LAM is inhaled albuterol. Albuterol can be given in a metered dose inhaler (MDI) or with a nebulizer. Researchers want to compare these methods to see which method best improves lung function in women with LAM. Objectives: \- To see whether a nebulizer or MDI can better improve lung function in women with LAM. Eligibility: \- Women at least 18 years of age who have impaired lung function because of LAM. Design: * Participants will be screened with a physical exam and medical history. No lab tests will be needed for this study. * Participants will have a 3-day overnight stay at the National Institutes of Health. Those who are using long-acting inhalers will have to stop taking these drugs 1 week before the study. * Participants will receive either the nebulizer or two or four puffs of the inhaler. Four puffs of albuterol is a higher dose than is normally prescribed, and is being tested on this study. * Participants will have each treatment around the same time of day on each of the 3 days. Before and after taking the albuterol, participants will have lung function tests.

Timeline

Start
2013-06-10
Primary completion
2027-11-01
Completion
2027-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Salbutamol Unknown 2 unknown Inhaled
Subject Salbutamol Unknown 4 unknown Inhaled
Subject Salbutamol Unknown Inhaled